Compare SCWO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCWO | ALGS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 34.6M |
| IPO Year | 2022 | 2020 |
| Metric | SCWO | ALGS |
|---|---|---|
| Price | $2.44 | $6.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 52.3K | ★ 145.1K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ 0.41 | N/A |
| Revenue | $215,037.00 | ★ $2,186,000.00 |
| Revenue This Year | $25,798.80 | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.19 | $3.98 |
| 52 Week High | $3.60 | $13.69 |
| Indicator | SCWO | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 57.43 |
| Support Level | $2.35 | $6.25 |
| Resistance Level | $2.81 | $7.05 |
| Average True Range (ATR) | 0.17 | 0.66 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 50.82 | 66.43 |
374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.